Search

Your search keyword '"MESH: Neoplasms, Multiple Primary"' showing total 10 results
Start Over Descriptor "MESH: Neoplasms, Multiple Primary"
10 results on '"MESH: Neoplasms, Multiple Primary"'

1. Synchronous primary neoplasia in patients with oropharyngeal cancer: Impact of tumor HPV status. A GETTEC multicentric study

Author

Florent Milliet, Emmanuel Chamorey, Guillaume Chambon, Laure Santini, Gilles Poissonnet, Alain Bizeau, Valérie Coste, Benjamin Lallemant, Olivier Dassonville, D. Culié, A. Modesto, Alexandre Bozec, H. Mirghani, Frederic Peyrade, Karen Benezery, Joanne Guerlain, Françoise Chapel, Thibault Galissier, Nicolas Fakhry, Agnès Dupret-Bories, Pascal Roger, Aicha Ben Lakdar, Anne Sophie Ramay, Julien Viotti, Renaud Garrel, Renaud Schiappa, Esma Saada-Bouzid, Florence Jourdan-Soulier, Stéphane Temam, Bruno Guelfucci, P. Gorphe, Anne Sudaka, Sébastien Vergez, Centre Hospitalier Universitaire de Nice (CHU Nice), Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL), UNICANCER-Université Côte d'Azur (UCA), Institut Universitaire du Cancer de Toulouse - Oncopole (IUCT Oncopole - UMR 1037), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer - Hôpital Sainte-Musse, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Assistance Publique - Hôpitaux de Marseille (APHM), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Pôle Biologie-Pathologie [CHRU Montpellier], Institut Gustave Roussy (IGR), Département de cancérologie cervico-faciale [Gustave Roussy] (CCF), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), and Salvy-Córdoba, Nathalie

Subjects
Oncology, Male, Cancer Research, MESH: Chi-Square Distribution, Multivariate analysis, Lung Neoplasms, Esophageal Neoplasms, Oropharynx, MESH: Logistic Models, Logistic regression, Neoplasms, Multiple Primary, Tertiary Care Centers, Tumor Status, 0302 clinical medicine, MESH: Neoplasms, Multiple Primary, MESH: Incidence, 030223 otorhinolaryngology, Fisher's exact test, Cancer, MESH: Human papillomavirus 16, Univariate analysis, Human papillomavirus 16, MESH: Middle Aged, Incidence, Smoking, MESH: Confidence Intervals, Middle Aged, Oropharyngeal Neoplasms, MESH: Cyclin-Dependent Kinase Inhibitor p16, 030220 oncology & carcinogenesis, MESH: Esophageal Neoplasms, symbols, Female, France, Oral Surgery, Second primary neoplasia, MESH: Smoking, medicine.medical_specialty, Alcohol Drinking, [SDV.CAN]Life Sciences [q-bio]/Cancer, Human papilloma virus, 03 medical and health sciences, symbols.namesake, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH: Analysis of Variance, Internal medicine, medicine, Confidence Intervals, MESH: Squamous Cell Carcinoma of Head and Neck, Humans, Cyclin-Dependent Kinase Inhibitor p16, Retrospective Studies, MESH: Tertiary Care Centers, Analysis of Variance, MESH: Humans, Chi-Square Distribution, business.industry, Squamous Cell Carcinoma of Head and Neck, MESH: Retrospective Studies, Retrospective cohort study, medicine.disease, Comorbidity, MESH: Male, MESH: Lung Neoplasms, MESH: France, Logistic Models, MESH: Oropharyngeal Neoplasms, business, MESH: Female, MESH: Alcohol Drinking
Abstract

International audience; Patients with oropharyngeal squamous cell carcinoma (OPSCC) display a significant risk of synchronous primary neoplasia (SPN) which could impact their management. The aims of this study were to evaluate the risk and distribution of SPN in OPSCC patients according to their HPV (p16) status, the predictive factors of SPN and the impact of SPN on therapeutic strategy and oncologic outcomes.Material and methods: All OPSCC patients treated from 2009 to 2014 were included in this multicentric retrospective study. Univariate analyses were conducted using Chi-2 and Fisher exact tests. For multivariate analyses, all variables associated with a p ≤ 0.10 in univariate analysis were included in logistic regression models.Results: Among the 1291 patients included in this study, 75 (5.8%) displayed a SPN which was preferentially located in the upper aerodigestive tract, lung and esophagus. Comorbidity level (p = 0.03), alcohol (p = 0.005) and tobacco (p = 0.01) consumptions, and p16 tumor status (p < 0.0001) were significant predictors of SPN. In multivariate analysis, p16+ status was significantly associated with a lower risk of SPN (OR = 0.251, IC95% [0.133;0.474]). Patients with a SPN were more frequently referred for non-curative treatment (p = 0.02). In patients treated with curative intent, there was no impact of SPN on the therapeutic strategy (surgical vs. non-surgical treatment). We observed no overall survival differences between patients with or without SPN.Conclusion: P16 tumor status is the main predictive factor of SPN in OPSCC patients. This study provides crucial results which should help adapt the initial work-up and the global management of OPSCC patients.

Published
2020
Full Text
View/download PDF

2. Multiple tumours in survival estimates

Author

Stefano Guzzinati, Florence Molinié, Rafael Marcos-Gragera, Eva Ardanaz, Tiziana Cassetti, Angel Izquierdo Font, Milena Sant, Stanislaw Gozdz, Rafael Peris-Bonet, Pascale Grosclaude, Emmanuel Desandes, Michel Coleman, Laura Ciccolallo, Lucia Mangone, Freddie Bray, Hermann Brenner, Giovanna Tagliabue, Mariano Santaquilani, Enrico Grande, Maria Zwierko, Jan Willem Coebergh, Emanuele Crocetti, Giulia Zigon, Roberta De Angelis, Stefano Ferretti, Andrea Tavilla, Gemma Gatta, Silvia Francisci, Paolo Contiero, Rosario Tumino, Laufey Tryggvadottir, Franco Berrino, Hans Storm, Paolo Baili, David Brewster, National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], Evaluative Epidemiology Unit, Fondazione IRCCS, Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Neurology, and Public Health

Subjects
Male, Oncology, Cancer Research, Survival, MESH : Age Distribution, MESH : Aged, MESH : Neoplasms, Multiple Primary, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Neoplasms, Multiple Primary, MESH: Aged, 80 and over, 0302 clinical medicine, Multiple Primary, Prostate, Neoplasms, Epidemiology, 80 and over, Cancer registries, MESH: Neoplasms, Multiple Primary, MESH : Female, 030212 general & internal medicine, Young adult, 10. No inequality, MESH : Sex Distribution, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, Relative survival, Medicine (all), MESH: Sex Distribution, Multiple tumours, Neoplasm, Adolescent, Adult, Age Distribution, Aged, Europe, Female, Humans, Middle Aged, Sex Distribution, Survival Analysis, Young Adult, Percentage point, MESH : Adult, 3. Good health, Multiple tumours - survival estimates, medicine.anatomical_structure, MESH: Young Adult, MESH: Survival Analysis, 030220 oncology & carcinogenesis, medicine.medical_specialty, MESH : Male, MESH : Europe, MESH : Young Adult, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, MESH : Adolescent, medicine, MESH : Middle Aged, MESH : Aged, 80 and over, MESH: Age Distribution, Survival analysis, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, MESH: Male, Surgery, Cancer registry, MESH: Europe, MESH : Survival Analysis, business, MESH: Female
Abstract

In international comparisons of cancer registry based survival it is common practice to restrict the analysis to first primary tumours and exclude multiple cancers. The probability of correctly detecting subsequent cancers depends on the registry's running time, which results in different proportions of excluded patients and may lead to biased comparisons. We evaluated the impact on the age-standardised relative survival estimates of also including multiple primary tumours. Data from 2,919,023 malignant cancers from 69 European cancer registries participating in the EUROCARE-4 collaborative study were used. A total of 183,683 multiple primary tumours were found, with an overall proportion of 6.3% over all the considered cancers, ranging from 0.4% (Naples, Italy) to 12.9% (Iceland). The proportion of multiple tumours varied greatly by type of tumour, being higher for those with high incidence and long survival (breast, prostate and colon-rectum). Five-year relative survival was lower when including patients with multiple cancers. For all cancers combined the average difference was -0.4 percentage points in women and -0.7 percentage points in men, and was greater for older registries. Inclusion of multiple tumours led to lower survival in 44 out of 45 cancer sites analysed, with the greatest differences found for larynx (-1.9%), oropharynx (-1.5%), and penis (-1.3%). Including multiple primary tumours in survival estimates for international comparison is advisable because it reduces the bias due to different observation periods, age, registration quality and completeness of registration. The general effect of inclusion is to reduce survival estimates by a variable amount depending on the proportion of multiple primaries and cancer site. (C) 2008 Elsevier Ltd. All rights reserved.

Published
2009
Full Text
View/download PDF

3. [STAG3 in premature ovarian failure]

Author

Caburet, Sandrine, Vilain, Éric, Institut Jacques Monod (IJM (UMR_7592)), Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Department of Human Genetics, David Geffen School of Medicine [Los Angeles], University of California [Los Angeles] (UCLA), University of California-University of California-University of California [Los Angeles] (UCLA), and University of California-University of California

Subjects
MESH: Consanguinity, MESH: Humans, MESH: Infertility, Female, MESH: Pedigree, MESH: Genomic Instability, MESH: Adult, MESH: Primary Ovarian Insufficiency, MESH: Sequence Deletion, MESH: Synaptonemal Complex, MESH: Genotype, MESH: Meiosis, MESH: Ovarian Neoplasms, MESH: Cell Cycle Proteins, MESH: Chromosomal Proteins, Non-Histone, MESH: Germ-Line Mutation, MESH: Neoplastic Syndromes, Hereditary, MESH: Neoplasms, Multiple Primary, MESH: Exons, MESH: Female, MESH: Nuclear Proteins, ComputingMilieux_MISCELLANEOUS, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

International audience

Published
2015
Full Text
View/download PDF

4. Métastase d'un carcinome mammaire dans un carcinome rénal. [Breast carcinoma metastasis into a renal cell carcinoma]

Author

Perrin, Christophe, Talarmin, Marie, Fontaine, Aurélie, Kerbrat, Pierre, Audrain, Odile, Rioux-Leclercq, Nathalie, Chiforeanu, Dan Cristian, Département d'oncologie médicale, CRLCC Eugène Marquis (CRLCC), Service d'anatomie et cytologie pathologiques [Rennes] = Anatomy and Cytopathology [Rennes], CHU Pontchaillou [Rennes], Cabinet d'anatomie et de cytologie pathologiques, Selarl O'Micro, Département d'informatique médicale, Institut de Génétique et Développement de Rennes (IGDR), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS), De Villemeur, Hervé, and Université de Rennes (UR)-Centre National de la Recherche Scientifique (CNRS)

Subjects
MESH: Combined Modality Therapy, MESH: Lymphatic Metastasis, education, Breast carcinoma, [SDV.CAN]Life Sciences [q-bio]/Cancer, Tumor-to-tumor metastasis, [SDV.MHEP.GEO]Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, urologic and male genital diseases, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Metastasis, Carcinome à cellules rénales, [SDV.CAN] Life Sciences [q-bio]/Cancer, Métastase intra-tumorale, MESH: Neoplasms, Multiple Primary, MESH: Incidental Findings, Métastase, MESH: Middle Aged, MESH: Humans, MESH: Carcinoma, Renal Cell, MESH: Bone Neoplasms, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Renal cell carcinoma, MESH: Lung Neoplasms, MESH: Nephrectomy, MESH: Carcinoma, Ductal, Breast, [SDV.MHEP.GEO] Life Sciences [q-bio]/Human health and pathology/Gynecology and obstetrics, MESH: Antineoplastic Combined Chemotherapy Protocols, MESH: Inflammatory Breast Neoplasms, Carcinome mammaire, MESH: Kidney Neoplasms, MESH: Female, MESH: Breast Neoplasms
Abstract

International audience; We report the case of a patient carrying a right breast carcinoma whose imaging exams showed lung and bone metastasic release, and incidentally synchronous right renal tumor. Histologic examination of the renal tumor found a mammary carcinoma metastasis into a clear renal cell carcinoma. This is the second case report of breast cancer with metastasis in a resected renal clear cell carcinoma.

Published
2011
Full Text
View/download PDF

5. [Early diagnosis of bronchial carcinoma after head and neck cancer]

Author

Bertrand, Dominique, Righini, Christian, Ferretti, Gilbert, Brambilla, Christian, Moro-Sibilot, Denis, Clinique de pneumologie, CHU Grenoble, Service d'ORL et de chirurgie cervicale, INSERM U823, équipe 2 (Bases Moléculaires de la Progression des Cancers du Poumon), Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)-Clinique de pneumologie, and Hurbin, Amandine

Subjects
Adult, Male, MESH: Neoplasms, Second Primary, Lung Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, Neoplasms, Multiple Primary, [SDV.CAN] Life Sciences [q-bio]/Cancer, Bronchoscopy, Humans, MESH: Neoplasms, Multiple Primary, Prospective Studies, MESH: Bronchoscopy, Aged, MESH: Aged, MESH: Middle Aged, MESH: Humans, Neoplasms, Second Primary, MESH: Adult, MESH: Carcinoma, Squamous Cell, Middle Aged, MESH: Prospective Studies, MESH: Male, MESH: Lung Neoplasms, MESH: Head and Neck Neoplasms, Carcinoma, Bronchogenic, MESH: Carcinoma, Bronchogenic, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Female, MESH: Tomography, Spiral Computed, Tomography, Spiral Computed, MESH: Female
Abstract

International audience; BACKGROUND: Patients with a previous history of cancer of the upper respiratory and digestive tracts (URDT) frequently develop a bronchial carcinoma (synchronous or metachronous) that may affect their survival. OBJECTIVE: To determine the prevalence of bronchial carcinoma at an early stage in a population of patients treated for cancer of the URDT. MATERIALS AND METHODS: This was a single centre prospective study (2002-2006). Patients in remission following treatment of cancers of the buccal cavity, pharynx (stages I -II) and larynx (stages I - III), were examined by a spiral CT scan and fibreoptic bronchoscopy (white light and autofluorescence), with biopsies, and cytology of the bronchial aspirate. RESULTS: 60 patients (55 men) were included. Two peripheral bronchial carcinomas were detected by scanning and two more (proximal) by endoscopy. All 4 bronchial tumours were squamous carcinomas (stage IA). Three patients had surgery, the fourth declined intervention. CONCLUSION: Our study confirms the high prevalence (6.7%) of bronchial carcinoma in patients with a past history of cancer of the URDT. It emphasises the complimentary roles of spiral scanning and bronchoscopy in early diagnosis. It is still too early to evaluate the impact of these investigations on the survival of the patients.

Published
2008

6. Report of a young man with three successive curable cancers

Author

M. Pavic, X. Pivot, J.P. Droz, M. Schell, A. Fléchon, Saas, Philippe, Service d'Oncologie Médicale [Centre hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Service d'oncologie pédiatrique, Centre Léon Bérard [Lyon], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])

Subjects
Oncology, medicine.medical_specialty, MESH: Combined Modality Therapy, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH: Wilms Tumor, MEDLINE, Salvage therapy, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Internal Medicine, Medicine, Combined Modality Therapy, MESH: Neoplasms, Multiple Primary, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, MESH: Humans, business.industry, MESH: Adult, MESH: Dysgerminoma, MESH: Male, MESH: Salvage Therapy, MESH: Antineoplastic Combined Chemotherapy Protocols, Extragonadal Germ Cell Tumor, 030220 oncology & carcinogenesis, MESH: Neoplasms, Germ Cell and Embryonal, [SDV.IMM]Life Sciences [q-bio]/Immunology, MESH: alpha-Fetoproteins, business
Abstract

International audience

Published
2008
Full Text
View/download PDF

7. [Melanoma in invisible naevus spilus]

Author

Livory, M., Descamps, V., Pelletier, Fabien, Maubec, Eve, Faivre, B., Marinho, E., Humbert, Philippe, Crickx, B., Aubin, François, Service de dermatologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Département de dermatologie, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Hôpital Saint-Jacques-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service d'Anatomie et cytologie pathologique, Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Saas, Philippe, Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques-Université de Franche-Comté ( UFC ), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)

Subjects
Male, Skin Neoplasms, genetic structures, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH: Melanoma, MESH : Male, MESH : Melanoma, MESH : Neoplasms, Multiple Primary, Neoplasms, Multiple Primary, MESH : Nevus, Pigmented, MESH: Nevus, Pigmented, Humans, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, MESH: Neoplasms, Multiple Primary, MESH : Middle Aged, skin and connective tissue diseases, Melanoma, Nevus, Pigmented, MESH: Humans, MESH: Middle Aged, MESH: Skin Neoplasms, MESH : Humans, MESH : Skin Neoplasms, Middle Aged, eye diseases, MESH: Male, [SDV.IMM]Life Sciences [q-bio]/Immunology
Abstract

International audience; BACKGROUND: Diagnosis of naevus lesions may be complex where they contain little or no pigmentation. Naevus spilus (or naevus on naevus) is, generally, readily identified by the difference in pigmentation between overlying and underlying naevi and healthy skin. Malignant transformation of naevus spilus is rare. We report two cases of melanoma in which surgical procedures revealed underlying melanocyte lesions, diagnosed at histology but undetectable on clinical examination. PATIENTS AND METHODS: Two patients were operated for melanoma in which surgery, at a site remote from the melanoma, suggested incomplete relapse despite the fact that previous clinical examination had indicated healthy skin. A diagnosis was made of melanoma in invisible naevus spilus. DISCUSSION: Diagnosis of melanoma in invisible naevus spilus may be suspected where several naevi are found together in a specific area. The main problem is the therapeutic stance to be adopted since complete excision of the underlying naevi is difficult in practice. Wood's light examination may be helpful.

Published
2008
Full Text
View/download PDF

8. Composite splenic marginal zone lymphoma and mantle cell lymphoma arising from 2 independent B-cell clones

Author

Christine Lefebvre, Mary Callanan, Anne Florin, Remy Gressin, Marie-Christine Jacob, Blandine Fabre, Laetitia Rabin, Jin Wang, Dominique Leroux, Claire Vettier, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de cancérologie et d'hématologie, CHU Grenoble-Hôpital Michallon, Laboratoire d'Immunocytologie, EFS, INSERM U823, équipe 7 (Voies Oncogéniques Des Hémopathies Malignes), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM)-Département de cancérologie et d'hématologie, CHU Grenoble-Hôpital Michallon-Hôpital Michallon, and Duley, Samuel

Subjects
Male, Pathology, Lymphoma, Mantle-Cell, [SDV.GEN] Life Sciences [q-bio]/Genetics, MESH: NF-kappa B p52 Subunit, Neoplasms, Multiple Primary, 0302 clinical medicine, Immunophenotyping, MESH: Lymphoma, Non-Hodgkin, immune system diseases, hemic and lymphatic diseases, MESH: Neoplasms, Multiple Primary, MESH: Aged, 0303 health sciences, education.field_of_study, Lymphoma, Non-Hodgkin, Immunohistochemistry, MESH: Splenic Neoplasms, 3. Good health, medicine.anatomical_structure, 030220 oncology & carcinogenesis, medicine.medical_specialty, Lymphoma, B-Cell, Population, Biology, Pathology and Forensic Medicine, 03 medical and health sciences, NF-kappa B p52 Subunit, Cyclin D, Cyclins, medicine, Humans, Splenic marginal zone lymphoma, education, B cell, Aged, 030304 developmental biology, MESH: Lymphoma, B-Cell, [SDV.GEN]Life Sciences [q-bio]/Genetics, MESH: Humans, Splenic Neoplasms, MESH: Immunohistochemistry, Gene rearrangement, medicine.disease, MESH: Cyclins, Molecular biology, MESH: Male, Lymphoma, Mantle cell lymphoma, MESH: Lymphoma, Mantle-Cell, CD5
Abstract

International audience; We report the first case of composite lymphoma involving both mantle cell lymphoma (MCL) and splenic marginal zone lymphoma (SMZL) with circulating villous lymphocytes. Morphological, immunohistochemical, immunophenotyping, as well as detailed genetic studies (fluorescence in situ hybridization, IGVH gene sequencing), were performed and confirmed the existence of 2 independent, unrelated tumor clones. The MCL component expressed IgMD lambda, was CD5+, harbored a t(11;14)(q13;q32) involving CCND1, and showed an unmutated VH1-18 gene rearrangement. The SMZL component expressed IgMD kappa, was CD5-, showed a t(10;14)(q24;q32) and an unmutated VH3-7 gene rearrangement. Interestingly, this t(10;14) targeted the NFKB2 gene. Only a single other case of SMZL with t(10;14)/NFKB2 has been reported. Taken together, these data indicate that the MCL and SMZL arose as a consequence of independent malignant transformation events within an antigen-naive B-cell population. This case highlights the importance of a multidisciplinary approach and tissue diagnosis in these complex situations.

Published
2007
Full Text
View/download PDF

9. Is there still a role for triple endoscopy as part of staging for head and neck cancer?

Author

Guardiola, Emmanuel, Chaigneau, Loïc, Villanueva, Christian, Pivot, Xavier, Service d'Oncologie Médicale [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), and Saas, Philippe

Subjects
MESH: Neoplasms, Second Primary, Lung Neoplasms, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH: Laryngoscopy, MESH: Endoscopy, Neoplasms, Multiple Primary, Bronchoscopy, Humans, MESH: Neoplasms, Multiple Primary, MESH: Bronchoscopy, Neoplasm Metastasis, MESH: Bronchial Neoplasms, Neoplasm Staging, MESH: Humans, Laryngoscopy, Bronchial Neoplasms, Endoscopy, Neoplasms, Second Primary, MESH: Carcinoma, Squamous Cell, MESH: Neoplasm Staging, MESH: Esophagoscopy, MESH: Neoplasm Metastasis, MESH: Lung Neoplasms, MESH: Head and Neck Neoplasms, Head and Neck Neoplasms, Carcinoma, Squamous Cell, [SDV.IMM]Life Sciences [q-bio]/Immunology, Esophagoscopy
Abstract

International audience; PURPOSE OF REVIEW: The use of tobacco and/or alcohol is linked with the occurrence of head and neck squamous cell carcinoma, esophagus cancer and lung cancer. If these carcinogenic factors can induce the development of a cancer in one of these locations, it would seem reasonable that a second cancer could appear in another of those areas, at the same time or at some point in the future. RECENT DEVELOPMENTS: This is the reason why one can consider that triple endoscopy is required as the optimal evaluation in patients with head and neck cancer. Nevertheless, the usefulness of this systematic procedure, which includes nasopharyngoscopy, laryngoscopy, pharyngoscopy, bronchoscopy and esophagoscopy, is debatable. The low number of head and neck cancers associated with synchronous primary cancers in the esophagus and/or lungs reported by several studies does not support this procedure and its morbidity. In contrast, in other studies a higher rate was observed and the authors pointed out the impact of such findings on treatment strategy, suggesting the benefit of routine triple endoscopy. One can conclude that the relevance of routine triple endoscopy is related to the rate of second synchronous primary cancer detected. A search to identify predictive factors of synchronous cancer occurrence will therefore be required. SUMMARY: This review summarizes the available data in the literature and highlights the need for selected patients with head and neck cancer to receive triple endoscopy.

Published
2006
Full Text
View/download PDF

10. Initial staging of squamous cell carcinoma of the oral cavity, larynx and pharynx (excluding nasopharynx). Part I: Locoregional extension assessment: 2012 SFORL guidelines

Author

S. Tronche, Stéphane Temam, J.-C. Ferrié, D. de Raucourt, Michel Lapeyre, C.-A. Righini, E. de Monès, Pierre-Yves Salaun, Sylvain Morinière, F. Lagarde, Sébastien Vergez, F. Dubrulle, B. Barry, Dominique Chevalier, Cécile Badoual, Chloé Bertolus, Philippe Schultz, Department of Head and Neck Surgery, Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse], Service d'ORL et de Chirurgie Cervico-Faciale (TOURS - ORL et CCF), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Service de Radiologie (LILLE - Radio), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Department of Nuclear Medicine, Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Department of Maxillofacial Surgery, CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de cancérologie cervico-faciale [Gustave Roussy] (CCF), Institut Gustave Roussy (IGR), Service d'ORL et de Chirurgie Cervico-Faciale (LILLE - ORL et CCF), Service d'ORL et de Chirurgie Cervico-Faciale (ORLEANS - ORL et CCF), Centre Hospitalier Régional d'Orléans (CHRO), Service d'ORL et de Chirurgie Cervico-Faciale (STRASBOURG - ORL et CCF), CHU Strasbourg, Service de Radiothérapie (CLERMONT FERRAND - Radiothérapie), CHU Clermont-Ferrand, Institut d'oncologie/développement Albert Bonniot de Grenoble (INSERM U823), Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Grenoble, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble, Service d'ORL et de Chirurgie Cervico-Faciale (PARIS - BICHAT - ORL et CCF), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), SFORL (SFORL), SFORL, Service d'Oto-Rhino-Laryngologie (O.R.L.) et de Chirurgie Cervico-Faciale [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), University Hospital Rangueil-Larrey, Service d'ORL et de Chirurgie Cervico-Faciale ( TOURS - ORL et CCF ), CHRU Tours, Service de Radiologie ( LILLE - Radio ), Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Groupe d'Etude de la Thrombose de Bretagne Occidentale ( GETBO ), Université de Brest ( UBO ), Service de Chirurgie Maxillo-Faciale ( PARIS - PSL - Chir Maxillo-Faciale ), Assistance publique - Hôpitaux de Paris (AP-HP), Département de cancérologie cervico-faciale [Gustave Roussy] ( CCF ), Institut Gustave Roussy ( IGR ), Service d'ORL et de Chirurgie Cervico-Faciale ( LILLE - ORL et CCF ), Service d'ORL et de Chirurgie Cervico-Faciale ( ORLEANS - ORL et CCF ), Centre Hospitalier Régional d'Orléans ( CHR ), Service d'ORL et de Chirurgie Cervico-Faciale ( STRASBOURG - ORL et CCF ), Service de Radiothérapie ( CLERMONT FERRAND - Radiothérapie ), Institut d'oncologie/développement Albert Bonniot de Grenoble ( INSERM U823 ), Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble-EFS-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble, Service d'ORL et de Chirurgie Cervico-Faciale ( PARIS - BICHAT - ORL et CCF ), Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], SFORL ( SFORL ), Service d'ORL et de Chirurgie Cervico-Faciale ( CAEN - ORL et CCF ), CHU Caen, Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO)-Université de Brest (UBO), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Institut National de la Santé et de la Recherche Médicale (INSERM)-EFS-CHU Grenoble-Université Joseph Fourier - Grenoble 1 (UJF)

Subjects
Larynx, MESH : Pharyngeal Neoplasms, MESH: Lymphatic Metastasis, [SDV]Life Sciences [q-bio], MESH : Mouth Neoplasms, MESH: Laryngeal Neoplasms, MESH : Neoplasms, Multiple Primary, Oral cavity, MESH : Neoplasm Invasiveness, MESH : Narrow Band Imaging, MESH: Magnetic Resonance Imaging, Neoplasms, Multiple Primary, MESH: Mouth Neoplasms, Narrow Band Imaging, 0302 clinical medicine, Squamous cell carcinoma, MESH: Cooperative Behavior, MESH: Narrow Band Imaging, Medicine, MESH: Microscopy, Confocal, MESH: Neoplasms, Multiple Primary, MESH : Neoplasm Staging, MESH : Endoscopy, Cooperative Behavior, MESH : Carcinoma, Squamous Cell, 030223 otorhinolaryngology, MESH: Multidetector Computed Tomography, MESH : Laryngeal Neoplasms, MESH : Evidence-Based Medicine, Evidence-Based Medicine, Microscopy, Confocal, MESH : Prognosis, medicine.diagnostic_test, MESH : Lymphatic Metastasis, MESH: Carcinoma, Squamous Cell, MESH: Neoplasm Staging, MESH : Cooperative Behavior, Prognosis, Magnetic Resonance Imaging, MESH : Interdisciplinary Communication, 3. Good health, MESH: Pharyngeal Neoplasms, medicine.anatomical_structure, Lymphatic Metastasis, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, Disease Progression, Mouth Neoplasms, MESH: Disease Progression, MESH: Interdisciplinary Communication, France, MESH : Multidetector Computed Tomography, medicine.medical_specialty, Tomodensitometry, MESH: Prognosis, MESH: Endoscopy, 03 medical and health sciences, MESH : Magnetic Resonance Imaging, Multidetector Computed Tomography, Carcinoma, Humans, Neoplasm Invasiveness, Basal cell, MESH : Microscopy, Confocal, MESH : France, Laryngeal Neoplasms, Neoplasm Staging, MESH: Humans, [ SDV ] Life Sciences [q-bio], business.industry, MESH : Humans, Head and neck cancer, Pharynx, Pharyngeal Neoplasms, Endoscopy, MESH : Disease Progression, Evidence-based medicine, MESH: Neoplasm Invasiveness, medicine.disease, Surgery, MESH: France, Otorhinolaryngology, Interdisciplinary Communication, business, MESH: Evidence-Based Medicine
Abstract

International audience; OBJECTIVES: To set out good practice guidelines for locoregional extension assessment of squamous cell carcinoma of the head and neck (excluding nasopharynx, nasal cavities and sinuses). MATERIALS AND METHODS: A critical multidisciplinary review of the literature on locoregional extension assessment of squamous cell carcinoma of the head and neck was conducted, applying levels of evidence in line with the French health authority's (HAS) literature analysis guide of January 2000. CONCLUSION: Based on the levels of evidence of the selected articles and on work-group consensus, graded guidelines are set out for clinical, endoscopic and imaging locoregional extension assessment of head and neck cancer.

Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results